Zydus Cadila Reels Under Double FDA Warning
This article was originally published in Scrip
Executive Summary
Shares of Cadila Healthcare were pounded on Indian bourses on New Year's eve after the FDA issued warning letters against two of the firm's sites, though the company's top brass stressed that de-risking efforts, by way of site transfers for critical products, were underway.